JP5346820B2 - Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体 - Google Patents

Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体 Download PDF

Info

Publication number
JP5346820B2
JP5346820B2 JP2009553239A JP2009553239A JP5346820B2 JP 5346820 B2 JP5346820 B2 JP 5346820B2 JP 2009553239 A JP2009553239 A JP 2009553239A JP 2009553239 A JP2009553239 A JP 2009553239A JP 5346820 B2 JP5346820 B2 JP 5346820B2
Authority
JP
Japan
Prior art keywords
antibody
seq
subtype
antibodies
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009553239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010521147A (ja
JP2010521147A5 (https=
Inventor
アントニオ・ランツァヴェッキア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs LLC
Original Assignee
Humabs LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs LLC filed Critical Humabs LLC
Publication of JP2010521147A publication Critical patent/JP2010521147A/ja
Publication of JP2010521147A5 publication Critical patent/JP2010521147A5/ja
Application granted granted Critical
Publication of JP5346820B2 publication Critical patent/JP5346820B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2009553239A 2007-03-13 2008-03-13 Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体 Expired - Fee Related JP5346820B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89461207P 2007-03-13 2007-03-13
US60/894,612 2007-03-13
PCT/IB2008/001527 WO2008110937A2 (en) 2007-03-13 2008-03-13 Antibodies against h5n1 strains of influenza a virus

Publications (3)

Publication Number Publication Date
JP2010521147A JP2010521147A (ja) 2010-06-24
JP2010521147A5 JP2010521147A5 (https=) 2011-05-06
JP5346820B2 true JP5346820B2 (ja) 2013-11-20

Family

ID=39760169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009553239A Expired - Fee Related JP5346820B2 (ja) 2007-03-13 2008-03-13 Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体

Country Status (5)

Country Link
US (2) US8124092B2 (https=)
EP (1) EP2125886A2 (https=)
JP (1) JP5346820B2 (https=)
CN (1) CN102046654A (https=)
WO (1) WO2008110937A2 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026375A2 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
JP2009502207A (ja) 2005-08-03 2009-01-29 フラウンホーファー ユーエスエー， インコーポレイテッド イムノグロブリンの産生のための組成物および方法
WO2008110937A2 (en) * 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus
WO2009009759A2 (en) 2007-07-11 2009-01-15 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
CA2731686C (en) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
GB0818356D0 (en) * 2008-10-07 2008-11-12 Istituto Superiore Di Sanito Antibodies
PL2350128T3 (pl) 2008-10-22 2015-03-31 Inst Res Biomedicine Sposoby wytwarzania przeciwciał z komórek plazmatycznych
CA2761648C (en) * 2009-05-11 2019-03-12 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
US8784819B2 (en) * 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
CA2807664A1 (en) * 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
CN102775469B (zh) * 2011-05-12 2018-02-09 厦门大学 甲型流感病毒核衣壳蛋白的抗原表位及其用途
AU2011373387B2 (en) 2011-07-18 2017-06-29 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
JP2013087069A (ja) * 2011-10-17 2013-05-13 Toyobo Co Ltd Ｈ５亜型インフルエンザウイルスを特異的に認識するモノクローナル抗体
MX367743B (es) 2011-12-05 2019-09-04 Trellis Bioscience Llc Anticuerpos utiles para la inmunizacion pasiva de influenza.
WO2013105896A1 (en) * 2012-01-12 2013-07-18 Temasek Life Sciences Laboratory Limited Monoclonal antibodies targeting neutralizing epitopes on h5 influenza virus of clade 2.3
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CN104968367B (zh) 2012-11-13 2018-04-13 弗·哈夫曼-拉罗切有限公司 抗血凝素抗体和使用方法
MX387277B (es) * 2013-03-14 2025-03-12 Contrafect Corp Composiciones basadas en anticuerpos neutralizantes suministrados intranasalmente para eficacia terapéutica aumentada.
SI3052192T1 (sl) 2013-10-02 2020-11-30 Medimmune, Llc Nevtralizarijoča protitelesa proti-influenci A in njihove uporabe
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6712428B2 (ja) 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
JP6614523B2 (ja) * 2014-03-28 2019-12-04 地方独立行政法人神奈川県立産業技術総合研究所 インフルエンザウイルスのｒｎａ依存性ｒｎａポリメラーゼのｐｂ２サブユニットに対するモノクローナル抗体
KR101628331B1 (ko) * 2014-03-28 2016-06-08 주식회사 녹십자엠에스 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법
MX392761B (es) 2014-07-15 2025-03-21 Medimmune Llc Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EA201792500A1 (ru) 2015-05-13 2018-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Aav-опосредованная экспрессия антител против гриппа и способы их использования
HUE056407T2 (hu) 2015-06-01 2022-02-28 Medimmune Llc Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
SG11201805001UA (en) 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
PL238020B1 (pl) 2016-09-12 2021-06-28 Inst Biotechnologii I Antybiotykow Kompozycja przeciwciał monoklonalnych przeciwko hemaglutyninie wirusów grypy serotypu H5 i jej zastosowanie, hybrydomy produkujące rzeczone przeciwciała, sposób diagnozowania infekcji wirusami grypy serotypu H5 oraz zestawy diagnostyczne
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
PT3589730T (pt) 2017-02-28 2024-02-28 Univ Pennsylvania Vetor de vírus adenoassociado (aav) de clado f e suas utilizações
UY37620A (es) 2017-02-28 2018-08-31 Univ Pennsylvania Vacunas contra la gripe mediadas por aav novedosas
MY201312A (en) 2017-06-02 2024-02-16 Pfizer Antibodies specific for flt3 and their uses
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP4087590A4 (en) * 2020-01-12 2024-05-15 Vanderbilt University HUMAN ANTIBODIES AGAINST CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS
WO2021202815A1 (en) * 2020-03-31 2021-10-07 Northeastern University Colorimetric and multiplexed isothermal rna-and antibody-based assay for sars-cov-2 and other viral diagnostics and cell analysis
CN114181302B (zh) * 2020-09-14 2023-03-24 东莞市朋志生物科技有限公司 针对甲型流感病毒的抗体、试剂盒和载体
US12319747B2 (en) * 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
WO2025245380A1 (en) * 2024-05-22 2025-11-27 Vanderbilt University Antibody generation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2817869B1 (fr) 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
CA2478973A1 (en) * 2002-03-13 2003-09-25 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
WO2007021002A1 (ja) 2005-08-19 2007-02-22 Bl Co., Ltd. インフルエンザウイルスｈ５亜型の免疫検出法
CA2622603C (en) 2005-09-15 2014-06-17 Crucell Holland B.V. Method for preparing immunoglobulin libraries
GB0522460D0 (en) 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
WO2007089753A2 (en) * 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
WO2007134327A2 (en) * 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
CN101541832B (zh) * 2006-09-07 2014-11-12 克鲁塞尔荷兰公司 能中和流感病毒h5n1的人结合分子及其应用
EP2450377A1 (en) 2006-09-07 2012-05-09 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
US20100150941A1 (en) 2006-09-13 2010-06-17 Dso National Laboratories Hemagglutinin antibody and uses thereof
AU2007295073A1 (en) 2006-09-15 2008-03-20 Fraunhofer Usa, Inc. Influenza antibodies, compositions, and related methods
WO2008110937A2 (en) * 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus

Also Published As

Publication number Publication date
CN102046654A (zh) 2011-05-04
US20100278834A1 (en) 2010-11-04
EP2125886A2 (en) 2009-12-02
JP2010521147A (ja) 2010-06-24
US20120114664A1 (en) 2012-05-10
WO2008110937A3 (en) 2009-04-30
WO2008110937A2 (en) 2008-09-18
US8124092B2 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
JP5346820B2 (ja) Ｈ５ｎ１亜型ａ型インフルエンザウィルスに対する抗体
JP6022515B2 (ja) 抗ａ型インフルエンザウイルス中和抗体およびその使用
JP6035332B2 (ja) Ａ型インフルエンザウイルス中和抗体及びその使用法
JP5814790B2 (ja) デングウイルス中和抗体およびその使用
CN110642944B (zh) 一种中和人感染h7n9甲型流感病毒的抗体及其用途
US10654915B2 (en) Antibodies useful in passive influenza immunization
WO2016109774A1 (en) Bispecific antibodies against plasma kallikrein and factor xii
CN113480640B (zh) 中和抗流感结合分子及其用途
WO2008125985A2 (en) Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
US20240092875A1 (en) Sars-cov-2 antibodies for treatment and prevention of covid-19
JP6101204B2 (ja) インフルエンザｈ５赤血球凝集素の主要中和エピトープに特異的なモノクローナル抗体
US20100061995A1 (en) Immunotherapy To Treat Or Prevent Viral Infection
JP2024536380A (ja) 抗ＳＡＲＳ－ＣｏＶ－２抗体及びその使用Ｉ
US20260035439A1 (en) Anti-Sars-COV-2 Antibodies and Uses Thereof
JP6622825B2 (ja) Ａ型インフルエンザウイルス中和抗体及びその使用法
US20220340644A1 (en) Influenza neutralizing antibodies and their uses
JP2017086068A (ja) Ａ型インフルエンザウイルス中和抗体及びその使用法
HK1260890B (zh) 登革热病毒中和抗体及其用途
HK1203410B (en) Antibodies useful in passive influenza immunization
HK1164898B (en) Dengue virus neutralizing antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130619

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130703

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130819

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees